Gracell Biotechnologies Inc.

GRCL

US38406L1035

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2023-12-05 pm EST			5-day change	1st Jan Change
5.08 ^USD	-3.42%		+12.89%	+120.87%

Dec. 05	Asian Equities Traded in the US as American Depositary Receipts Trend Lower Again in Tuesday Trading	MT
Nov. 29	Asian Equities Traded in the US as American Depositary Receipts Edge Higher in Wednesday Trading	MT

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Gracell Biotechnologies Inc.

Asian Equities Traded in the US as American Depositary Receipts Trend Lower Again in Tuesday Trading	Dec. 05	MT
Asian Equities Traded in the US as American Depositary Receipts Edge Higher in Wednesday Trading	Nov. 29	MT
ADRs Advance; Redhill Biopharma Ltd. Climbs 128%	Nov. 28	DJ
Cabaletta Bio Down as FDA Looks Into Issues With Several Companies' Approved CAR T Drugs	Nov. 28	DJ
Gracell Biotech Shares Rise on FDA Clearance of Early Trial of Refractory Systemic Lupus Erythematosus Treatment	Nov. 27	MT
Asian Equities Traded in the US as American Depositary Receipts Open Week Lower in Monday Trading	Nov. 27	MT
Evercore ISI Starts Gracell Biotechnologies With Outperform Rating	Nov. 27	MT
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus	Nov. 27	CI
Financial Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Higher in Friday Trading	Nov. 24	MT
Transcript : Gracell Biotechnologies Inc., Q3 2023 Earnings Call, Nov 13, 2023	Nov. 13	CI
Gracell Biotechnologies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Asian Equities Traded in the US as American Depositary Receipts Surge in Friday Trading	Nov. 03	MT
Gracell Biotechnologies to Present Updated Results from BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 65h American Society of Hematology Annual Meeting & Exposition	Nov. 02	CI
Gracell Biotechnologies Inc. to Present Data Highlighting Preclinical Efficacy of Smart Cart Against Solid Tumors At Society for Immunotherapy of Cancer 38th Annual Meeting	Oct. 31	CI
Stifel Starts Gracell Biotechnologies With Buy Rating, Price Target is $11	Oct. 19	MT
Asian Equities Traded in the US as American Depositary Receipts Fall Sharply in Tuesday Trading	Oct. 03	MT
Gracell Biotechnologies Reports Updated Clinical Data for Fastcar-T Gc012f for High-Risk, Newly Diagnosed Multiple Myeloma, Demonstrating 100% Stringent Complete Response Rate	Sep. 27	CI
Gracell Biotechnologies Doses First Person in Phase 1b/2 Trial in US of GC012F to Treat Multiple Myeloma	Sep. 26	MT
Gracell Biotechnologies Doses First Patient in Phase 1B/2 Clinical Trial in U.S. Evaluating GC012F for Treatment of Relapsed/Refractory Multiple Myeloma	Sep. 26	CI
Financial Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Sharply Lower in Tuesday Trading	Sep. 26	MT
Asian Equities Traded in the US as American Depositary Receipts Move Lower in Friday Trading	Sep. 15	MT
Transcript : Gracell Biotechnologies Inc. Presents at Citi 18th Annual BioPharma Conference, Sep-07-2023 01:50 PM	Sep. 07	CI
Citigroup Trims Gracell Biotechnologies Price Target to $11 From $12, Maintains Buy Rating	Aug. 29	MT
Asian Equities Traded in the US as American Depositary Receipts Move Slightly Lower Thursday	Aug. 24	MT
HC Wainwright Adjusts Gracell Biotechnologies' Price Target to $13 From $12, Keeps Buy Rating	Aug. 14	MT

Chart Gracell Biotechnologies Inc.

Duration

Period

More charts

Gracell Biotechnologies Inc is a China-based clinical-stage biopharmaceutical company focused on discovering and developing cell therapies for the treatment of cancers. The Company is primarily focused on disrupting conventional approaches to chimeric antigen receptor (CAR) thymus (T) cell therapies by leveraging its technology platforms FasTCAR and TruUCAR. With FasTCAR, the Company is able to deliver younger, less exhausted T cells for autologous cell therapies with enhanced activities and next-day manufacturing. With TruUCAR, the Company is able derive T cells from non-human leukocyte antigen (HLA)-matched healthy donors to generate allogeneic CAR-T cell therapies. The Company is levering its technology platform to develop various drug candidates, including GC012F, GC019F, GC007F, GC027 and GC007g.

Sector

Biotechnology & Medical Research

Calendar

2023-12-11 - American Society of Hematology Meeting - Abstract number: #1022

More about the company

Income Statement Evolution

More financial data

Ratings for Gracell Biotechnologies Inc.

Trading Rating :

Investor Rating :

ESG Refinitiv :

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.08USD

Average target price

11.71USD

Spread / Average Target

+130.60%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GRACELL BIOTECHNOLOGIES INC.	+120.87%	487 M $
SEAGEN INC.	+67.95%	40 719 M $
IQVIA HOLDINGS INC.	+4.60%	39 112 M $
MODERNA, INC.	-56.42%	29 847 M $
LONZA GROUP AG	-26.37%	28 329 M $
ICON PUBLIC LIMITED COMPANY	+38.74%	22 187 M $
ALNYLAM PHARMACEUTICALS, INC.	-28.31%	21 380 M $
CELLTRION, INC.	+1.31%	17 155 M $
UNITED THERAPEUTICS CORPORATION	-13.59%	11 293 M $
BIO-TECHNE CORPORATION	-22.32%	10 182 M $

Other Biotechnology & Medical Research

Gracell Biotechnologies Inc.

Equities

GRCL

US38406L1035

Biotechnology & Medical Research

EPS Revisions